ORAGENICS INC

For the period ended Dec 31, 2024. Filed Mar 14, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 14, 2025

OGEN$0.35+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ (DEFICIT) EQUITY

Common Stock · Preferred Stock · Additional Paid In · Accumulated · Total Shareholders’ (Deficit)
	Shares	Amount	Shares	Amount	Capital	Deficit	Equity
Balances at December 31, 2022	2,024,657	$2,025	9,467,000	$1,592,723	$196,977,071	$(185,562,517)	$13,009,302
Compensation expense relating to option issuances	—	—	—	—	550,083	—	550,083
Compensation expense relating to restricted stock issuances	140,000	140	—	—	466,605	—	466,745
Issuance of Series F preferred stock	—	—	8,000,000	—	8,947,834	—	8,947,834
Conversion of Series F preferred stock to common stock	511,308	511	(511,803)	—	(511)	—	—
Common stock issued in private placement	404,728	405	—	—	849,522	—	849,927
Net loss	—	—	—	—	—	(20,655,737)	(20,655,737)
Balances at December 31, 2023	3,080,693	$3,081	16,955,197	$1,592,723	$207,790,604	$(206,218,254)	$3,168,154
Compensation expense relating to option issuances	—	—	—	—	516,049	—	516,049
Sale of common stock	5,548,378	5,578	—	—	6,663,553	—	6,669,860
Conversion of Series A and B preferred Stock to common stock	22,528	22	(9,467,000)	(1,592,723)	1,592,701	—	—
Conversion of prefunded warrants to common stock	3,888,501	3,889	—	—	(1,190)	—	1,970
Net loss	—	—	—	—	—	(10,567,918)	(10,567,918)
Balances at December 31, 2024	12,570,100	$12,570	7,488,197	$—	$216,561,717	$(216,786,172)	$(211,885)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.